Share on StockTwits

Northwest Biotherapeutics (NASDAQ:NWBO) announced its earnings results on Wednesday. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.29) by $0.24, American Banking News reports.

Northwest Biotherapeutics (NASDAQ:NWBO) opened at 6.38 on Wednesday. Northwest Biotherapeutics has a 52-week low of $3.10 and a 52-week high of $10.64. The stock has a 50-day moving average of $6.5 and a 200-day moving average of $6.48. The company’s market cap is $379.6 million.

Northwest Biotherapeutics, Inc is a development-stage company. The Company focuses on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.